Welcome to our dedicated page for Enlivex SEC filings (Ticker: ENLV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Enlivex Therapeutics Ltd. (ENLV) files its regulatory reports with the U.S. Securities and Exchange Commission as a foreign private issuer, and these SEC filings provide detailed insight into the company’s clinical operations and digital asset treasury strategy. On this page, you can review Enlivex Form 6-K reports covering topics such as the ENX-CL-05-001 Phase I/II trial of Allocetra™ in moderate-to-severe knee osteoarthritis, including three- and six-month topline data, as well as shareholder letters discussing the company’s strategic roadmap for Allocetra™ and knee osteoarthritis development.
Filings also document Enlivex’s capital markets and treasury activities. Recent Form 6-K submissions describe a large private placement of ordinary shares and pre-funded warrants, the associated securities purchase agreement and registration rights agreement, and the intended use of proceeds to implement a digital asset treasury strategy centered on the RAIN token. Additional exhibits outline a treasury management agreement for handling digital asset accounts, a shareholders’ agreement with lock-up and voting provisions, and an exclusive option agreement with the RAIN foundation to purchase RAIN tokens within a specified period.
Corporate governance and shareholder matters appear in filings related to annual and extraordinary general meetings, including notices, proxy statements, and voting outcomes. Financial statement packages and operating and financial review and prospects are furnished on Form 6-K for interim periods, providing unaudited condensed consolidated financial information and management discussion. Through this filings page, users can access Enlivex’s SEC-reported information in one place, while AI-powered tools can help summarize lengthy documents, highlight key terms of financing and treasury agreements, and surface clinical and risk factor disclosures that are most relevant to ENLV’s business in macrophage reprogramming immunotherapy and its RAIN-focused digital asset treasury policy.
Enlivex Ltd. filed a Form F-3 shelf prospectus to register up to 23,333,333 ordinary shares for resale by a selling shareholder. These shares are issuable upon conversion or repayment of a $21.0 million senior secured convertible promissory note issued in a private placement that closed on March 23, 2026.
The Note was purchased for $19.0 million, matures on March 23, 2027, and has an initial conversion price of $2.69175 per share. The company will not receive proceeds from resales; net proceeds go to the selling shareholder. The registration permits resale "from time to time" once the statement is declared effective.
Enlivex Ltd. reports that Denmark’s medicines regulator has approved its Clinical Trial Application for a Phase 2b trial of Allocetra™ in moderate-to-severe age-related primary knee osteoarthritis. This follows recent FDA clearance and supports a global, randomized, double-blind, placebo-controlled study enrolling patients in the United States, Denmark and Poland.
The trial will test intra-articular injections of Allocetra™ with key efficacy endpoints focused on pain and physical function at three and six months, plus quality-of-life and mobility measures. Enlivex also highlights its dual focus on developing Allocetra™ for inflammatory, aging-related conditions and operating a prediction markets treasury strategy built around the Rain protocol.
Enlivex Ltd. reports that Ondo Finance has launched ENLVon, a tokenized representation of Enlivex’s ordinary shares on Ondo’s Global Markets platform. This structure lets non-U.S. retail and institutional investors gain economic exposure to Enlivex through blockchain-based digital infrastructure.
ENLVon can be held in compatible digital wallets, transferred subject to platform and regulatory requirements, and used within a growing ecosystem of financial applications, including as collateral or in lending and yield strategies. The model supports fractional exposure with low minimum investment and near‑instant settlement, aligning Enlivex with the expanding tokenized securities market.
Enlivex Ltd. reported that the Rain Foundation, which oversees the decentralized Rain prediction markets protocol, has launched an AI agent-ready interface and a $5 million grant program. The initiative aims to help developers and creators build, launch, and monetize independent prediction market platforms via AI agents such as OpenClaw.
Enlivex’s CEO highlighted that the company is a major holder of the RAIN token and views Rain’s new single‑prompt market creation as a forward-looking concept. The company believes future revenue growth of the Rain protocol and the appropriation of approximately 2.5% of total trading volume to automatic RAIN token buy-and-burn could benefit RAIN’s value and support Enlivex’s digital asset treasury strategy.
Enlivex Ltd. files its Annual Report on Form 20-F for the year ended December 31, 2025, outlining a dual strategy that combines clinical-stage immunotherapy with a crypto-based treasury model. The company is developing Allocetra™, an off-the-shelf cell therapy targeting osteoarthritis and other inflammatory conditions by reprogramming macrophages to a homeostatic state.
Enlivex has established a digital asset treasury centered on the RAIN governance token, acquired using $212 million of gross proceeds from a November 24, 2025 private placement. The report warns that fair value accounting for these digital assets under ASU 2023-08 could create significant volatility in reported earnings and the carrying value of its crypto holdings.
The company has incurred operating losses since inception, has retained earnings of approximately $1.1 billion as of December 31, 2025, and has not generated product revenue. Management expects existing resources to fund planned operations, including product development, through the end of 2027, but highlights the need for substantial additional capital thereafter and notes that its ability to continue as a going concern depends on securing further financing. Extensive risk factors are detailed, including clinical, regulatory, manufacturing, competitive, cybersecurity, product liability and ESG-related risks, as well as risks from cryptocurrency market volatility and evolving digital asset regulation.
Enlivex Ltd. reported a strong turnaround for the year ended December 31, 2025, with net income of $1.23 billion and diluted earnings per ordinary share of $25.48. Management explains that these earnings were driven primarily by appreciation in the value of its treasury and treasury-related derivative assets.
The company describes itself as a quality longevity business powered by a prediction markets treasury. Its dual strategy pairs development of Allocetra™, an immunotherapy targeting inflammatory conditions of aging such as age-related osteoarthritis, with a treasury model built around the RAIN decentralized prediction markets protocol.
Enlivex is hosting an earnings webcast at 09:00 am Eastern Time to discuss these results and its outlook, available via online registration and through the investor relations section of its website.
Enlivex Ltd. entered a $21 million senior secured convertible note financing with Lind Global, receiving net proceeds of approximately $18.7 million. The note matures in March 2027, is repayable in nine monthly installments and can be repaid or converted into ordinary shares at $2.69175 per share.
The debt is secured by certain digital asset accounts, including Enlivex’s RAIN token portfolio. The board approved a share repurchase program of up to $20 million of ordinary shares. Enlivex’s option to buy up to 278,181,818,181 RAIN tokens at $0.0033 per token was extended to December 31, 2027, and the company partially exercised the option to acquire about 3.03 billion RAIN tokens for $10 million.
Enlivex Ltd. reported that the U.S. FDA has cleared its Investigational New Drug (IND) application for Allocetra™, enabling a global Phase 2b trial in patients with moderate-to-severe age-related primary knee osteoarthritis. The randomized, double-blind, placebo-controlled study will test intra-articular injections of Allocetra™ for pain, physical function, quality of life and mobility outcomes.
The company describes this as its first regulatory clearance since adopting a dual-engine strategy that combines a clinical-stage quality longevity program with a prediction markets treasury built around the RAIN protocol.
ENLV is updating an at-the-market offering: it is now offering up to $250,000,000 of ordinary shares for sale pursuant to an At-The-Market Sales Agreement with BTIG, LLC.
The supplement notes the company initially registered up to $299,553,108 under the agreement and that, from November 24, 2025 through the supplement date, the company sold an aggregate of 1,936,660 ordinary shares for aggregate gross proceeds of $2,513,111. Sales may be made from time to time in at-the-market transactions under the Sales Agreement; the offering amount here excludes shares previously sold under the Prospectus.
Enlivex Ltd. Chief Executive Officer Oren Hershkovitz filed an initial ownership report showing his current equity position in the company. He directly holds 172,855 Ordinary Shares, each with a par value of NIS 0.40.
He also holds employee stock options to acquire 150,000 Ordinary Shares at an exercise price of $8.19 per share that expire on December 31, 2033, and options to acquire an additional 60,000 Ordinary Shares at an exercise price of $5.34 per share that expire on November 17, 2032. This filing does not reflect new purchases or sales but establishes his existing holdings.